Glitazone: Profile of a new substance class;Glitazone: Profil einer neuen substanzklasse

Internist

Volumn 42, Issue 4, 2001, Pages 587-596

  Janka, H U ^a  

^a II Medizinische Abteilung   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

CARDIOVASCULAR DISEASE; DIALYSIS; DRUG MECHANISM; HEMODILUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTOPERATIVE COMPLICATION; REVIEW;

ALBUMINURIA; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHROMANS; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; THIAZOLES; THIAZOLIDINEDIONES; UNITED STATES;

EID: 0035073512     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050793     Document Type: Review

References (60)

1. Hepatocellular injury in a patient receiving rosiglitazone
2. Rosiglitazon
3. Homeostasis model assessment of insulin resistance predicts cardiovascular disease in type 2 diabetes mellitus
4. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
5. Effect of renal impairment on the pharmacokinetics of rosiglitazone (RSG)
6. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity
7. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentrations in NIDDM patients
8. Association of lipid levels over time with clinical outcomes in patients with type-2-diabetes in the UKPDS
9. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
10. A study of the effect of age on the pharmaco-kinetics of BRL 49653C in healthy volunteers
11. Pharmaco-kinetics of pioglitazone in patients with renal impairment
12. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes
13. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus
14. Hepatic failure in a patient taking rosiglitazone
15. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans
16. Effect of food on the pharmacokinetics of pioglitazone
17. Pioglitazone
18. Low-dose rosiglitazone enhances glycemic control when combined with sulfonylureas in type 2 diabetes
19. Mechanisms and clinical effects of thiazolidinediones
20. Dyslipidemia and hypertension in newly diagnosed diabetic subjects: Is it due to hyperglycemia or the prediabetic state: Findings from the San Antonio Heart Study (SAHS)
21. Insulin sensitivity in subjects with type 2 diabetes
22. Pharmacokinetic study of AD-4833 in the elderly
23. Five-year incidence of coronary heart disease related to major risk factors and metabolic control in newly-diagnosed non-insulin-dependent diabetes
24. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by ballon catheterization
25. Pioglitazone suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK coupling with Pyk2
26. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
27. Efficacy and metabolic effects of metformin and troglitazone in type-2-diabetes mellitus
28. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects
29. Insulinresistenz und kardiovaskuläre Komplikationen
30. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPAR-gamma in endothelial function
31. Rosiglitazone increases pancreatic islet area, number and insulin content, but not insulin gene expression
32. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action
33. Expression of peroxisome proliferator-activated mRNA in isolated human panreatic islets
34. Effect of pioglitazone on glucose tolerance and insulin sensitivity in diet-controlled type 2 diabetic subjects
35. Relationship between HbA1c and weight in the treatment of patients with type 2 diabetes
36. Troglitazone improved diabetic nephropathy in patients with type 2 diabetes
37. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM)
38. Effect of pioglitazone on glucose metabolism in sulfonylurea-treated patients with type 2 diabetes
39. Pioglitazone time-dependently reduces tumor necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats
40. Rosiglitazone treatment reduces gamma-glutamyltransferase levels, a marker for visceral and hepatic fat
41. Relationship between hypertriglyceridemia and insulin sensitivity: An euglycemic clamp study
42. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes
43. Gamma-Glutamyltransferase is related to insulin resistance independently of body mass index
44. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome
45. Improved insulin sensitivity and beta cell responsivity suggested by HOMA analysis of pioglitazone therapy
46. Echocardiographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone
47. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials
48. Rosiglitazone therapy is not associated with hepatotoxicity
49. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
50. Long-term echocardiographic assessment in patients with type2 diabetes mellitus treated with pioglitazone
51. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes
52. Prevention of diabetes does not completely prevent insulin secretory defects in ZDF rat
53. Troglitazone decreases the proportion of srnall, dense LDL and increases the resistance of LDL to oxidation in obese subjects
54. Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patients
55. Pioglitazone inhibits plasminogen activator inhibitor-1 expression in human vascular smooth muscle cell
56. In vitro inhibitory effects of troglitazone and ist metabolites on drug oxidation activities of human cytochrome P45O enzymes: Comparisin with pioglitazone and rosiglitazone
57. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats